london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal


Aflibercept good results in refractory ranibizumab cases

Poster Details

First Author: P.Udaondo SPAIN

Co Author(s):    R. Martinez-Costa   A. Cisneros-Lanuza               0   0 0   0 0   0 0   0 0

Abstract Details


to evaluate the functional and anatomic response of patients with wet AMD treated with ranibizumab after switching to aflibercept


Try to analyze the role of aflibercept in refractory cases and the possibility of extending interval treatment in AMD patients that could let us doing a better treatment according to real daily practice


in this is retrospective study we included 15 eyes with active lesions treated with ranibizumab that switched to aflibercept to either control the disease or extend the treatment interval


in all cases the treatment interval could be extended; in 4 cases up to 12 weeks. 4 eyes with retinal epithelium detachment that had partially responded to ranibizumab had a dramatic response to aflibercept. All cases had and anatomical improvement shown in the OCT but only 10 cases improved visual acuity maybe due to the long evolution of the disease in those cases. No side effects were observed during the 12 months follow up period


aflibercept was efficient in cases that had partially responded to ranibizumab and allowed to extend the treatment in cases that needed monthly ranibizumab injections.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy